<?xml version="1.0" encoding="UTF-8"?> <rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0"> <channel> <title>Repositorio Institucional de la Universidad de Granada</title> <link>https://digibug.ugr.es:443</link> <description>El repositorio digital DIGIBUG captura, almacena, indexa, preserva y distribuye materiales de investigación en formato digital.</description> <pubDate xmlns="http://apache.org/cocoon/i18n/2.1">Sat, 15 Mar 2025 07:00:12 GMT</pubDate> <dc:date>2025-03-15T07:00:12Z</dc:date> <item> <title>Blood Plasma, Fibrinogen or Fibrin Biomaterial for the Manufacturing of Skin Tissue-Engineered Products and Other Dermatological Treatments: A Systematic Review</title> <link>https://hdl.handle.net/10481/103093</link> <description>Blood Plasma, Fibrinogen or Fibrin Biomaterial for the Manufacturing of Skin Tissue-Engineered Products and Other Dermatological Treatments: A Systematic Review Sierra Sánchez, Álvaro; Sanabria de la Torre, Raquel; Ubago Rodríguez, Ana Dolores; Quiñones Vico, María Isabel; Montero Vílchez, Trinidad; Sánchez Díaz, Manuel; Arias Santiago, Salvador Antonio The use of blood plasma, fibrinogen or fibrin, a natural biomaterial, has been widely studied for the development of different skin tissue-engineered products and other dermatological treatments. This systematic review reports the preclinical and clinical studies which use it alone or combined with other biomaterials and/or cells for the treatment of several dermatological conditions. Following the PRISMA 2020 Guidelines, 147 preclinical studies have revealed that the use of this biomaterial as a wound dressing or as a monolayer (one cell type) skin substitute are the preferred strategies, mainly for the treatment of excisional or surgical wounds. Moreover, blood plasma is mainly used alone although its combination with other biomaterials such as agarose, polyethylene glycol or collagen has also been reported to increase its wound healing potential. However, most of the 17 clinical reviewed evaluated its use for the treatment of severely burned patients as a wound dressing or bilayer (two cell types) skin substitute. Although the number of preclinical studies evaluating the use of blood plasma as a dermatological treatment has increased during the last fifteen years, this has not been correlated with a wide variety of clinical studies. Its safety and wound healing potential have been proved; however, the lack of a standard model and the presence of several approaches have meant that its translation to a clinical environment is still limited. A higher number of clinical studies should be carried out in the coming years to set a standard wound healing strategy for each dermatological disease. This review has been funded by the Instituto de Salud Carlos III through the project PI17/02083 (co-funded by the European Regional Development Fund “A way to make Europe”) and by the Regional Government of Andalusia (PIGE-0242-2019). The work of Álvaro Sierra-Sánchez was supported by a predoctoral fellowship (BOE 05/01/2018) funded by Instituto de Salud Carlos III (co-funded by European Social Fund “Investing in your future”) with the dossier number FI18/00269. This study is part of his doctoral research in the Biomedicine program of the University of Granada (Spain).; Supplementary Materials. &#13; The following supporting information can be downloaded at:&#13; https://www.mdpi.com/article/10.3390/jfb16030079/s1 </description> <guid isPermaLink="false">https://hdl.handle.net/10481/103093</guid> </item> <item> <title>Frozen Shoulder as a Metabolic and Immune Disorder: Potential Roles of Leptin Resistance, JAK-STAT Dysregulation, and Fibrosis</title> <link>https://hdl.handle.net/10481/103092</link> <description>Frozen Shoulder as a Metabolic and Immune Disorder: Potential Roles of Leptin Resistance, JAK-STAT Dysregulation, and Fibrosis Navarro Ledesma, Santiago Frozen shoulder (FS) is a complex and multifactorial condition characterized by persistent inflammation, fibrosis, and metabolic dysregulation. Despite extensive research, the underlying drivers of FS remain poorly understood. Recent findings indicate the coexistence of pro-inflammatory and fibrosis-resolving macrophages within affected tissues, suggesting a dysregulated immune response influenced by metabolic and neuroendocrine factors. This review proposes that leptin resistance, a hallmark of metabolic syndrome and chronic inflammation, may play a central role in FS pathogenesis by impairing macrophage polarization, perpetuating inflammation, and disrupting fibrosis resolution. The JAK-STAT signaling pathway, critically modulated by leptin resistance, may further contribute to immune dysregulation by sustaining inflammatory macrophage activation and interfering with tissue remodeling. Additionally, FS shares pathogenic features with fibrotic diseases driven by TGF-β signaling, mitochondrial dysfunction, and circadian disruption, further linking systemic metabolic dysfunction to localized fibrotic pathology. Beyond immune and metabolic regulation, alterations in gut microbiota, bacterial translocation, and chronic psychosocial stress may further exacerbate systemic inflammation and neuroendocrine imbalances, intensifying JAK-STAT dysregulation and leptin resistance. By examining the intricate interplay between metabolism, immune function, and fibrotic remodeling, this review highlights targeting leptin sensitivity, JAK-STAT modulation, and mitochondrial restoration as novel therapeutic strategies for FS treatment. Future research should explore these interconnections to develop integrative interventions that address both the metabolic and immune dysregulation underlying FS, ultimately improving clinical outcomes. </description> <guid isPermaLink="false">https://hdl.handle.net/10481/103092</guid> </item> <item> <title>Drawing Attention and Shaping Beliefs and Self-Efficacy: Evaluating the Persuasive Effectiveness of Corrective and Recommendation Messages in Responsible Gambling</title> <link>https://hdl.handle.net/10481/103091</link> <description>Drawing Attention and Shaping Beliefs and Self-Efficacy: Evaluating the Persuasive Effectiveness of Corrective and Recommendation Messages in Responsible Gambling Sánchez-Fernández, Francisco-Luis; Casado Aranda, Luis Alberto; Martínez Fiestas, Myriam; Ibáñez Zapata, José Ángel </description> <guid isPermaLink="false">https://hdl.handle.net/10481/103091</guid> </item> <item> <title>Magnetic activated carbon particles as stimuli-responsive vehicles for methotrexate</title> <link>https://hdl.handle.net/10481/103090</link> <description>Magnetic activated carbon particles as stimuli-responsive vehicles for methotrexate Lirio Piñar, Juan Antonio; Lázaro Callejón, Marina; Iglesias Salto, Guillermo Ramón; Romacho, Tania; Delgado Mora, Ángel Vicente; García García, Gracia; Ahualli Yapur, Silvia Alejandra This study investigates porous activated carbon (AC) particles as drug delivery vehicles for methotrexate (MTX). To enhance functionality, magnetic nanoparticles are embedded in AC imparting superparamagnetic properties (MAC composites), making them suitable for controlled transport and localization, as well as for facilitating their response to external fields. The composites are further functionalized with branched low molecular weight polyethyleneimine (PEI) to confer them a positive charge. After characterizing size, composition, and magnetic hysteresis, their potential as MTX carriers is assessed. Electrophoretic mobility and infrared data confirm the presence of magnetite, polymer, and drug molecules. Photothermal therapy (PTT) tests reveal that MAC–PEI particles produce up to 180 W g−1 of specific absorption rate (SAR) under infrared laser radiation. Due to its anisotropy, rotating magnetic fields (RMF) induce particle rotation, offering another external stimulus. Biocompatibility studies with human skin M1 fibroblasts confirm no significant cytotoxicity at concentrations below 700 μg mL−1. The particles adsorb over 80% of MTX from 0.6 mM solutions, with release evaluated at pH 5.8 under PTT and RMF stimuli. Both methods significantly enhance MTX release, achieving twice the drug release compared to passive conditions, demonstrating the particles’ high potential as active vehicles for targeted MTX delivery. </description> <guid isPermaLink="false">https://hdl.handle.net/10481/103090</guid> </item> <item> <title>Therapeutic Management in Patients with Chronic Obstructive Pulmonary Disease Who Are Overweight or Obese: A Systematic Review and Meta-Analysis</title> <link>https://hdl.handle.net/10481/103089</link> <description>Therapeutic Management in Patients with Chronic Obstructive Pulmonary Disease Who Are Overweight or Obese: A Systematic Review and Meta-Analysis Chami-Peña, Sara; Caballero Vázquez, Alberto; Mebrive-Jiménez, María José; Gómez Urquiza, Jose Luis; Romero Béjar, José Luis; Caballero-Mateos, Antonio M.; Cañadas De La Fuente, Guillermo Arturo Introduction/Objective: The relationship between chronic obstructive pulmonary disease (COPD) and overweight is complex and multifaceted, as these conditions can interact in terms of symptoms, severity and clinical management. To analyse the clinical and therapeutic management of patients suffering from COPD and overweight. Methods: This systematic review was carried out, in accordance with the PRISMA statement, during November 2024, following a search of the Medline/PubMed databases. The search equation used, with MESH descriptors, was: “(Pulmonary Disease, Chronic Obstructive OR COPD) AND (obesity OR overweight)”. Both inclusion and exclusion criteria were applied, focusing on the selection of clinical trials. The studies were classified into two main groups: by their focus on the relationship between overweight/obesity and COPD; and by the benefits provided by physical exercise to patients with these conditions. A random-effects meta-analysis was performed on the data obtained. The protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42024576389). Results: The search produced nine relevant clinical trials with a total of 1345 COPD patients. Four of the trials incorporated obesity (BMI ≥ 30) as an inclusion criterion, while the other five had mixed samples, with patients presenting either overweight or obesity (four patients with BMI ≥ 25 and one with BMI ≥ 27). The risk of bias tool for randomised trials showed that all nine studies had a low risk of bias. Overall, these studies highlight the importance of overweight management and reject the use of extreme measures. Furthermore, they confirm the association between overweight/obesity and COPD, for which this condition is a risk factor, to a degree depending on the BMI. Four studies reported significant improvements in the clinical management of COPD patients following appropriate physical exercise. Specifically, one study observed that supervised exercise improved cardio-vascular performance; another, that observed that aquatic exercise increased maximal capacity, endurance and quality of life; another, that found cycling improved ventilatory performance; and the fourth, that observed exercise complementary to standard therapy in hospitalised obese COPD patients improved strength, exercise capacity and other perceived variables such as anxiety, mobility and dyspnoea. Conclusions: The therapeutic management of overweight COPD patients should include weight control, physical exercise and appropriate pharmacological treatment. Physical exercise is associated with improvements in endurance, exercise capacity, cardio-vascular performance, ventilatory performance and strength. In addition, the participants in these studies self-perceived clinical improvement. These findings justify the performance of further RCTs examining the role of physical exercise in patients with COPD and overweight/obesity, in order to improve their clinical outcomes and quality of life. </description> <guid isPermaLink="false">https://hdl.handle.net/10481/103089</guid> </item> </channel> </rss>